Next Choice nonprescription, too
This article was originally published in The Tan Sheet
Watson Laboratories receives FDA's clearance for nonprescription sale of its Next Choice emergency contraceptive - a generic verson of Plan B (levonorgestrel 1.5 mg) - to consumers 17 and older as Plan B's original period of nonprescription exclusivity runs out for Teva Pharmaceutical Industries. Watson began shipping nonprescription Next Choice to major retail drug chains shortly after FDA's Aug. 28 approval of its abbreviated new drug application, with pharmacies in some markets expected to start selling the product the next day, said Patty Eisenhaur, the firm's VP of investor relations and corporate communications. The subsidiary of Morristown, N.J.-based Watson Pharmaceuticals previously received FDA's OK to market Next Choice as a prescription product and began shipping it early this summer. Teva carved out another three years of exclusivity in the branded nonprescription EC market with FDA's July approval of Plan B One-Step, which combines the two 0.75-mg doses of the original product into a single tablet (1"The Tan Sheet" July 20, 2009)
You may also be interested in...
Teva Pharmaceutical Industries likely will gain another three years of exclusivity in the branded nonprescription emergency contraceptive market with FDA's approval of a revised dosage of Plan B
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.
The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.